Skip to main content

Table 2 Cancer risk compared with the general population and relative risk in the TNFi-exposed vs biologic naïve participants

From: Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study

  Risk in biologic-naïve RA patients Risk in TNFi-exposed patients TNFi-exposed vs biologic-naïve patients
Observed Expected SIR* (95% CI) Observed Expected SIR (95% CI) RR (95% CI)
All invasive cancers 49 32.27 1.52 (1.16, 2.02) 107 102.62 1.04 (0.87, 1.27) 0.71 (0.46, 1.08)
Melanoma 4 2.65 1.51 (0.57, 5.35) 12 9.17 1.31 (0.76, 2.46) 1.18 (0.29, 4.70)
Lung 9 3.35 2.69 (1.43, 5.68) 16 9.45 1.69 (1.05, 2.90) 0.38 (0.12, 1.20)
Lymphoid cancers 5 2.71 1.84 (0.78, 5.47) 15 8.24 1.82 (1.12, 3.18) 0.79 (0.25, 2.55
Bowel 7 4.59 1.53 (0.74, 3.66) 10 13.11 0.76 (0.42, 1.54) 0.75 (0.17, 3.29)
Prostate 10 4.75 2.10 (1.18, 4.12) 12 13.67 0.88 (0.51, 1.64) 0.67 (0.23, 1.99)
Breast 8 4.58 1.75 (0.90, 3.86) 17 19.35 0.88 (0.56, 1.47) 0.50 (0.22, 1.16)
  1. SIR Standardised Incidence Ratio, CI confidence interval, RR relative risk